ArticleScientific reports2026
Green synthesis of Ag/ZnO nanocomposites from Phyllanthus emblica seed for multifunctional wound healing applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Green synthesis and characterization of Ag and ZnO nanoparticles and Ag@ZnO nanocomposites usingRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents an efficient and eco-friendly approach for synthesizing ZnO and SZ (Ag/ZnO NPs) nanocomposites using PE (Phyllanthus emblica) seed extract as a reducing agent. UV-vis, XRD, FESEM, EDX and elemental analysis, FT-IR, and AFM were used to characterize zinc oxide and SZ nanocomposites. PE seed extract was used to synthesize zinc oxide and SZ nanocomposites, which had an average particle size of 31.19 and 50.15 nm. Then the antibacterial activity was assessed against Salinivibrio proteolyticus, Bacillus subtilis, and Staphylococcus epidermidis using the agar well diffusion technique. Maximum inhibition zones were observed for SZ nanocomposites (14 mm, 16 mm, and 13 mm), demonstrating their antibacterial activity. Furthermore, the MTT-assay were used to assess the cytotoxicity of ZnO and SZ nanocomposites in NIH-3T3 fibroblast cell lines. The study revealed that ZnO and varying concentrations of SZ NCs (0.5%, 1%, 1.5%, and 2%) showed different in vitro cell survival rates. When treated with SZ nanocomposites at concentrations of 50-250 µg/mL for 24 h, the corresponding survival rates were 189.05 µg/mL to 57.83 µg/mL, respectively. Compared to other weight percentages, the 1.5% SZ NCs demonstrate significant antibacterial and cytotoxic activities. Furthermore, following in vitro studies of antioxidant, anti-inflammatory, and wound-healing assays of 1.5% SZ nanocomposites showed significant efficacy. These findings suggest that the nanocomposites are promising candidates for the treatment of antibacterial and wound-healing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.